<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399905</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00004133</org_study_id>
    <nct_id>NCT01399905</nct_id>
    <nct_alias>NCT00745277</nct_alias>
  </id_info>
  <brief_title>High and Low Dose Carbidopa Treatment of Parkinson's Disease</brief_title>
  <official_title>A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: We hypothesize that carbidopa in daily doses of 450mg will enter the central
      nervous system and partially inhibit AAAD, thereby reducing the decarboxylation of exogenous
      levodopa to dopamine, and thereby blunt the therapeutic effects of levodopa in PD subjects.

      The purpose of this study is to see how low dose vs. high dose of the study drug, carbidopa
      effect movement in subjects with Parkinson's disease. The low dose of the study drug is 75 mg
      and the high dose is 450mg.

      Subjects will be recruited from the investigators clinic when they are seen for treatment for
      Parkinson's disease. Subjects will also be recruited through flyers hung at OHSU and at the
      VA.

      Subjects will take part in 2 screening visits one week apart to determine eligibility.
      Subjects will be randomly chosen to start either high or low dose carbidopa and take it for 4
      weeks. Subjects will be called 2, 4, and 6 or 7 days after this visit to ask how they are
      doing after starting this dose of study drug. We will leave them a message if we cannot reach
      them. If there are any problems, we will schedule them to come to the clinic within the next
      2 days.

      Subjects will have an outpatient visit 2 weeks after screening and a hospital admission 2
      weeks after that. At the hospital, subjects will stay for 3 days. They will have blood drawn
      and their Parkinson's disease assessed by a finger tapping exercise, timing their walking,
      and looking at their uncontrolled movements.

      The subject will then receive the opposite dose of carbidopa for 4 weeks. Subjects will be
      called 2, 4, and 6 or 7 days after this visit to ask how they are doing after starting this
      dose of study drug. We will leave them a message if we cannot reach them. If there are any
      problems, we will schedule them to come to the clinic within the next 2 days.

      The outpatient visit and hospital admission will repeat again. At the end of the second
      hospital admission, treatment on the study is over and subjects will go back to their
      original Parkinson's disease medications. The study will end with a follow up phone call or
      clinic visit 2 - 4 weeks after the final hospital admission.

      Subjects will fill out a daily diary that asks about their movement throughout the day for 3
      days before they come to the Oregon Clinical and Translational Research Institute.

      Carbidopa is used for the treatment of Parkinson's disease with levodopa. This protocol is
      using a high dose of 450mg of carbidopa. This study is also using IV levodopa, which is a
      different route than is normally given.

      Finger tapping rates will be compared between high and low dose study drug use to see if one
      group has slower rates than the other.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Specific Aims:

      Parkinson's disease is a common neurodegenerative disorder characterized by the progressive
      motor symptoms of tremor, rigidity, and bradykinesia. The prevalence is estimated at
      102-109/100,000 and increases with age. It is the second most common neurodegenerative
      disorder after Alzheimer's disease, and the annual cost in the US is estimated to be $14.3
      billion dollars per year.

      In Parkinson's disease (PD) dopamine containing neurons in the substantia nigra are
      selectively lost, which causes motor dysfunction. Dopamine levels may be increased by giving
      oral levodopa, which improves motor function in PD. After oral administration, levodopa is
      taken into the brain and converted into dopamine by aromatic amino acid decarboxylase (AAAD)
      enzyme in the striatum , resulting in improved dopaminergic neurotransmission. AAAD is found
      in the peripheral tissues as well as in the brain, and prior to passage into the central
      nervous system levodopa may be decarboxylated to dopamine in the small bowel and liver.
      Peripheral metabolism of levodopa to dopamine significantly reduces the amount of levodopa
      that reaches the brain and therefore dopamine available for neurotransmission. The presence
      of dopamine in the periphery also produces anorexia and nausea. Carbidopa is an AAAD
      inhibitor that reduces the conversion of levodopa to dopamine. It is thought to not cross the
      blood-brain barrier and to affect only peripheral AAAD. This concept is of fundamental
      importance in the current treatment of PD. Carbidopa potentiates levodopa so that a much
      lower dose is effective. It also reduces anorexia and nausea, which often occur after giving
      levodopa alone. For this reason, almost all levodopa is marketed as carbidopa/levodopa
      tablets. This combination drug has become the standard of care for PD. As the disease
      progresses, increasingly high amounts of the carbidopa/levodopa combination are given to
      ensure adequate motor functioning, though the response to treatment becomes much less
      predictable with frequent fluctuations in motor ability.

      Though conventional wisdom and older pharmacological studies suggest carbidopa does not
      penetrate the blood-brain barrier, recent animal studies contradict this. This is very
      important because if carbidopa entered the central nervous system in humans it could
      significantly inhibit levodopa conversion into dopamine, and thus reduce its therapeutic
      effects. A single large dose of carbidopa given to a normal rat, or a rat chemically lesioned
      to mimic PD, resulted in carbidopa entrance into the central nervous system, and inhibition
      of brain AAAD and conversion of levodopa to dopamine (1, 2). It is not known whether
      prolonged use of high dose carbidopa worsens motor function over time in humans. A small
      series of patients with PD and motor fluctuations that were switched from carbidopa/levodopa
      to levodopa alone were reported to have improvement in motor features(3). Carbidopa is
      typically given in a one to four ratio of carbidopa to levodopa in each pill, and chronic
      high dosing of caribopa and levodopa is common in PD. If carbidopa penetrates into the
      central nervous system in humans it could lead to decreased conversion of levodopa to
      dopamine in the central nervous system, and decrease the therapeutic response to administered
      levodopa.

      We propose a randomized, double blind, controlled trial with crossover to explore two
      mechanisms by which carbidopa may accumulate in the CNS.

      If given in high doses over 4 weeks, carbidopa may slowly accumulate in the central nervous
      system and impair dopamine synthesis and thereby motor function in PD.

      Aim #1: Compare motor response to 2 hour levodopa infusion after 4 weeks of high dose
      carbidopa and after 4 weeks of low dose carbidopa.

      After 4 weeks of high dose carbidopa, subjects may notice more &quot;off&quot; time than after 4 weeks
      of low dose carbidopa. Changes in response to levodopa can be evaluated by a patient diary
      and by the need to increase daily levodopa.

      Aim 2: Determine the clinical response to oral levodopa at the end of a 4 weeks treatment
      with high dose carbidopa and with low dose carbidopa measured by an &quot;on/off&quot; diary and with
      total daily levodopa dose.

      An alternate reason for carbidopa to enter the central nervous system (CNS) is through a
      blood-brain barrier that has become abnormal as a result of age and PD. In this case a single
      large dose of carbidopa may enter the CNS and reduce the conversion of levodopa to dopamine.

      Aim #3: Compare the clinical response to 2 hour levodopa infusion administered with 25mg
      carbidopa or 150mg carbidopa.

      Demonstrating that high doses of carbidopa diminishe the response to levodopa would alter
      current practice, as clinicians presently are not concerned about the quantity of carbidopa
      administered to patients with PD. As a result of this study, a significant insight into the
      management of advanced PD will be gained. The overall goal is to better understand if use of
      high dose carbidopa may paradoxically complicate treatment. A positive or negative finding
      will have important therapeutic implications. This study has potential to fundamentally
      change how we treat PD.

      B. Background and Significance:

      B. 1 Parkinson's Disease

      PD is a common neurodegenerative disorder that results in progressive tremor, rigidity, and
      bradykinesia. The risk for developing PD increases with age. The prevalence ranges from
      102-109/100,000 in Western countries and incidence rate of 1.7 per 1000 person years(4, 5).
      There is increased direct cost to the individual and a substantial indirect cost to the
      family(6, 7). The overall estimated cost of PD in the US is $14.3 billion dollars
      annually(8).

      Though PD is associated with a variety of clinical features, patients typically present with
      motor dysfunction. Motor signs are caused by loss of dopaminergic neurons in the substantia
      nigra. The mainstay of treatment for motor signs is correction of dopaminergic
      neurotransmission by oral administration of levodopa, a precursor of dopamine. The risk of
      death in PD is significantly reduced by the use of levodopa and responsiveness to levodopa
      treatment is a strong predictor of survival(9, 10).

      B. 2. Pharmacology of Levodopa and Carbidopa Levodopa is taken up by the small bowel and
      heavily metabolized by AAAD located in the intestinal mucosa, and to a lesser degree by the
      liver. As a result of this first pass peripheral metabolism, the bioavailability of levodopa
      in the serum after oral administration is approximately 30%(11) and peripheral metabolism of
      levodopa continues after the first pass metabolism so that only a small amount of levodopa
      enters the CNS if AAAD is not inhibited. Carbidopa is an AAAD inhibitor and can be given
      along with levodopa to prevent the peripheral conversion of levodopa to dopamine, and
      increase the overall bioavailability of levodopa by two to fourfold. Higher doses of
      carbidopa produce higher plasma levels of levodopa. Carbidopa is also of clinical importance
      since carbidopa reduces anorexia and nausea related to the effects of dopamine on the area
      postrema which is effectively outside the blood-brain barrier.

      Traditional clinical thinking assumes carbidopa does not penetrate the blood brain barrier,
      and by this virtue will not interfere with central conversion of levodopa to dopamine (12).
      The studies supporting this assumption rely on animal models and utilize single doses of
      carbidopa (13)(14). Clinical dictum indicates a minimum of 75 milligrams of carbidopa be
      given daily to produce reasonable inhibition of the AAAD. Aside from the primary effect of
      inhibiting the decarboxylation of levodopa in the periphery and potentiating the effects of
      levodopa, carbidopa has no demonstrated pharmacological effect. Since carbidopa is not
      thought to penetrate the blood brain barrier it is considered a peripheral decarboxylase
      inhibitor.

      B. 3. Carbidopa Acts Centrally to Prevent Formation of Dopamine Evidence from laboratory
      studies has appeared in recent years suggesting carbidopa penetrates the blood brain barrier
      to a greater extent than realized. One piece of evidence is based on single injection models
      using microdialysate techniques for drug level measurement in normal rats (1). A single high
      dose of carbidopa 50mg/kg may inhibit the aromatic amino acid decarboxylase activity in the
      striatum of normal rats by 75% (2). Benserazide is a peripheral AAAD inhibitor similar to
      carbidopa. Benserazide administration 50mg/kg prolongs the time to reach peak dopamine level
      by 60 minutes centrally. Administration of benserazide 10mg/kg and 50mg/kg decreases striatal
      AAAD activity in normal rats by 28% and 78% respectively, and in rats modeled to mimic PD
      benserazide 10mg/kg and 50mg/kg decreases striatal AAAD activity 75% and 88%, respectively
      (15). Even if a small percent of each dose of carbidopa enters the CNS, long-term use could
      allow carbidopa to accumulate if clearance of carbidopa is not rapid. A small study suggests
      that motor fluctuations improve in advanced PD when patients receive levodopa without an
      aromatic amino acid decarboxylase inhibitor (3). It was demonstrated in an earlier study with
      an experimental formulation of extended release carbidopa/levodopa that some patients had
      worse motor function with three times the dose of carbidopa/levodopa despite an adequate
      plasma levodopa level (16). High dose carbidopa is typically used in advanced PD. When high
      dose carbidopa is given chronically this may create a situation where carbidopa accumulates
      in the central nervous system and could thereby worsen motor function.

      B. 4. Alteration of the Blood Brain Barrier in PD May Be a Mechanism by Which Carbidopa
      Inhibits Central AAAD Another consideration is that the blood brain barrier is altered in PD
      and could allow entry of substances previously sequestered to the periphery (17). As PD
      progresses patients receive larger doses of carbidopa along with levodopa in order to manage
      motor fluctuations. Chronic levodopa administration often results in dyskinesias in these
      circumstances. Histochemical evidence from animal models of levodopa induced dyskinesia
      suggests there is dysfunction of the blood brain barrier. Signs of angiogenesis and serum
      albumin leakage were two findings supporting vascular alteration in this model (18). Chronic
      administration of MPTP to primates increases VEGF-expressing neurons and increases the number
      of blood vessels in the substantia nigra pars comptacta (19). Similarly, in the
      6-hydroxydopamine model of PD, primates had patchy loss of blood brain barrier in the same
      regions associated with angiogenesis (20). In a small autopsy study humans with PD had
      vascularity present in the substantia nigra pars compacta compared with controls (21). Blood
      brain barrier alteration could lead to increased penetration of carbidopa from the periphery
      over time in two different scenarios. Firstly, carbidopa clearing mechanisms and transport
      pumps may be overwhelmed if small amounts accumulate over time. Secondly, the degree of
      blood-brain barrier alteration may be so great that even a single large dose of carbidopa may
      enter the CNS.

      Carbidopa penetrates the blood brain barrier to a limited extent after a single injection in
      normal rats. Since the blood brain barrier could be altered in PD there might be significant
      inhibition of central AAAD. Either the effect of long-term multiple daily doses of carbidopa
      or a single large dose of carbidopa could lead to a significant decrease in the amount of
      available dopamine, thereby worsening the clinical features of PD.

      C. Preliminary Studies / Experience of the Investigators:

      Our group has extensive experience in randomized controlled clinical trials and proof of
      principle studies in PD. This includes a large number of levodopa infusion protocols similar
      to that proposed for the current study. We have recently completed studies examining the dose
      effect of apomorphine on motor fluctuations (Gunzler in press), clinical testing of
      concomitantly dosed levodopa and methylphenidate (22), and evolution of response to levodopa
      over the course of PD (23). We have conducted pilot studies involving both outpatient and
      Clinical Translational Research Center (CTRC formerly GCRC) admissions for both levodopa and
      carbidopa (16, 24). Furthermore we have been involved in research on the basic pharmacology
      and clinical effects of levodopa (25-35).

      D. Research Design and Methods

      D. 1. Overall Study Design This study will be a randomized, double-blind, \controlled,
      crossover trial of four week outpatient treatment periods with levodopa and either carbidopa
      450mg daily or carbidopa 75mg daily plus placebo (figure 1). Levodopa will be dosed
      separately in individual capsules at doses and intervals that maximize motor function.
      Subjects will be selected based on inclusionary and exclusionary criteria and randomized to
      start in either high dose carbidopa group or low dose carbidopa group. After randomization
      subjects will be given four weeks of outpatient treatment with levodopa and either high dose
      carbidopa or low dose carbidopa plus placebo. After this four week treatment phase subjects
      will be brought into the Clinical Translational Research Center at OHSU (CTRC) for a total of
      three days. Included in this will be two days measuring objective motor function with
      levodopa infusion along with a different dose of carbidopa on each of the two days. The
      evening of admission to the CTRC subjects will turn in ratings of outpatient clinical state
      collected in a structured diary. After this visit they will crossover and alternately receive
      either high dose carbidopa or low dose of carbidopa for another four weeks. They will again
      be brought into the CTRC for a second two day measurement of motor function with levodopa
      infusion and a different dosing schedule of carbidopa on each of the two days. They will
      again turn in ratings of outpatient clinical state collected in a structured diary. Both
      subjects and investigators will remain blinded to the dose of carbidopa for both outpatient
      phases and one of the two days of each inpatient phase of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Tapping Speed</measure>
    <time_frame>Performed every 30 minutes from 8 AM to 2 PM</time_frame>
    <description>Tapping speed is an index of bradykinesia and is used as a response to levodopa infusion.
Reported as increase over average of three measurements between 8 AM and 9 AM (baseline tapping speed) as (taps/min)*(hours) for tapping scores from beginning of levodopa infusion to 3 hours after conclusion of levodopa infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of Levodopa Plasma Concentrations Above Baseline</measure>
    <time_frame>Measured every 30 minutes from 9 AM until 2 PM</time_frame>
    <description>Baseline value is levodopa concentration at 9 AM. AUC is calculated as levodopa concentrations minus 9 AM value at 30 minute intervals until 2 PM.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>High carbidopa followed by low carbidopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low carbidopa followed by high carbidopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbidopa</intervention_name>
    <description>75 mg of carbidopa per day versus 450 mg of carbidopa per day</description>
    <arm_group_label>High carbidopa followed by low carbidopa</arm_group_label>
    <arm_group_label>Low carbidopa followed by high carbidopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's disease

          -  Treatment with carbidopa/levodopa

          -  Motor fluctuations

        Exclusion Criteria:

          -  Dementia

          -  Hallucinations

          -  Age greater than 85
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John G Nutt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2020</results_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>John G. Nutt</investigator_full_name>
    <investigator_title>Director, Parkinson Center of Oregon</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Carbidopa</keyword>
  <keyword>Blood brain barrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Movement Disorders Clinic at Oregon Health and Science University in Portland, Oregon.</recruitment_details>
      <pre_assignment_details>Of the 17 subjects screened, 14 subjects met enrollment criteria and were randomized into one of the two treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Carbidopa Followed by High Carbidopa</title>
          <description>75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day for four weeks</description>
        </group>
        <group group_id="P2">
          <title>High Carbidopa Followed by Low Carbidopa</title>
          <description>450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">Subject withdrew from the study before receiving treatment.</participants>
                <participants group_id="P2" count="6">Subject was treated at least one dose of carbidopa before withdrawing from the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Carbidopa Followed by High Carbidopa</title>
          <description>75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day for four weeks</description>
        </group>
        <group group_id="B2">
          <title>High Carbidopa Followed by Low Carbidopa</title>
          <description>450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="6"/>
                    <measurement group_id="B2" value="65" spread="5"/>
                    <measurement group_id="B3" value="63" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Tapping Speed</title>
        <description>Tapping speed is an index of bradykinesia and is used as a response to levodopa infusion.
Reported as increase over average of three measurements between 8 AM and 9 AM (baseline tapping speed) as (taps/min)*(hours) for tapping scores from beginning of levodopa infusion to 3 hours after conclusion of levodopa infusion.</description>
        <time_frame>Performed every 30 minutes from 8 AM to 2 PM</time_frame>
        <population>All 12 participants who completed the study were included in the data analysis. Each arm contains data from all 12 participants because this is a cross-over study. All participants participated in both the high-dose and low-dose carbidopa arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Carbidopa (75 mg/Day) Day 1</title>
            <description>Day 1 of levodopa infusions following 4 weeks of low-dose carbidopa (75 mg/day). Carbidopa 25 mg administered at 8 AM, 10 AM and 12 PM for day 1 infusion.</description>
          </group>
          <group group_id="O2">
            <title>Low-dose Carbidopa (75 mg/Day) Day 2</title>
            <description>Day 2 of levodopa infusions following 4 weeks of low-dose carbidopa (75 mg/day). Carbidopa 25 mg administered at 8 AM, 10 AM, and 12 PM for day 2 infusion.</description>
          </group>
          <group group_id="O3">
            <title>High-dose Carbidopa (450 mg/Day) Day 1</title>
            <description>Day 1 of levodopa infusions following 4 weeks of high-dose carbidopa (450 mg/day). Carbidopa 25 mg administered at 8 AM 10 AM and 12 PM for day 1 infusion.</description>
          </group>
          <group group_id="O4">
            <title>High-dose Carbidopa (450 mg/Day) Day 2</title>
            <description>Day 2 of levodopa infusions following 4 weeks of high-dose carbidopa (450 mg/day). Carbidopa 150 mg administered at 8 AM, 10 AM and 12 PM for day 2 levodopa infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Tapping Speed</title>
          <description>Tapping speed is an index of bradykinesia and is used as a response to levodopa infusion.
Reported as increase over average of three measurements between 8 AM and 9 AM (baseline tapping speed) as (taps/min)*(hours) for tapping scores from beginning of levodopa infusion to 3 hours after conclusion of levodopa infusion.</description>
          <population>All 12 participants who completed the study were included in the data analysis. Each arm contains data from all 12 participants because this is a cross-over study. All participants participated in both the high-dose and low-dose carbidopa arms.</population>
          <units>(taps/min)*(hours)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="103"/>
                    <measurement group_id="O2" value="141" spread="131"/>
                    <measurement group_id="O3" value="145" spread="123"/>
                    <measurement group_id="O4" value="201" spread="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Levodopa Plasma Concentrations Above Baseline</title>
        <description>Baseline value is levodopa concentration at 9 AM. AUC is calculated as levodopa concentrations minus 9 AM value at 30 minute intervals until 2 PM.</description>
        <time_frame>Measured every 30 minutes from 9 AM until 2 PM</time_frame>
        <population>The levodopa plasma samples of one subject were accidently thawed so samples from 11 participants were used in this data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Carbidopa (75 mg/Day) Day 1</title>
            <description>Day 1 of levodopa infusions following 4 weeks of low-dose carbidopa (75 mg/day). Carbidopa 25 mg administered at 8 AM, 10 AM and 12 PM for day 1 infusion.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Carbidopa (450 mg/Day) Day 1</title>
            <description>Day 1 of levodopa infusions following 4 weeks of high-dose carbidopa (450 mg/day). Carbidopa 25 mg administered at 8 AM, 10 AM and 12 PM for day 1 infusion.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Carbidopa (75 mg/Day) Day 2</title>
            <description>Day 2 of levodopa infusions following 4 weeks of low-dose carbidopa (75 mg/day). Carbidopa administered at 8 AM, 10 AM and 12 PM for day 2 infusion.</description>
          </group>
          <group group_id="O4">
            <title>High-dose Carbidopa (450 mg/Day) Day 2</title>
            <description>Day 2 of levodopa infusions following 4 weeks of high-dose carbidopa (450 mg/day). Carbidopa 150 mg administered at 8 AM, 10 AM and 12 PM on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Levodopa Plasma Concentrations Above Baseline</title>
          <description>Baseline value is levodopa concentration at 9 AM. AUC is calculated as levodopa concentrations minus 9 AM value at 30 minute intervals until 2 PM.</description>
          <population>The levodopa plasma samples of one subject were accidently thawed so samples from 11 participants were used in this data analysis.</population>
          <units>(Âµg/ml)*(hours)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="1.38"/>
                    <measurement group_id="O2" value="5.91" spread="1.64"/>
                    <measurement group_id="O3" value="5.23" spread="1.23"/>
                    <measurement group_id="O4" value="6.13" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low-dose Carbidopa (75 mg/Day)</title>
          <description>Due to the cross-over study design all 12 participants who completed the study are included in both the high-dose and low-dose treatment arms.</description>
        </group>
        <group group_id="E2">
          <title>High-dose Carbidopa (450 mg/Day)</title>
          <description>Due to the cross-over study design all 12 participants who completed the study are included in both the high-dose and low-dose treatment arms. In addition, the subject who initiated treatment but did not complete the study is included in this arm for the purpose of reporting adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostasis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty swallowing study drug</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Voice fading</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body aches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Increased dyskinesia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>More off time/tremor</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania/anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>worsening hypersensitivity pneumonitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small study with limited quantity of patients</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John G. Nutt, MD</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-9054</phone>
      <email>nuttj@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

